Clinical trials: Climacteric Symptoms
- Condition Climacteric Symptoms
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Dehydration, Menstruation
Hydration & Female Life Stages
Female life stages including premenopausal, perimenopausal, postmenopausal, are characterized by changing concentrations and patterns of hormones.
- Conditions
- Dehydration, Menstruation, Pre-menopause, Peri-menopausal Women
- Trial name
- NCT07653620
- Testing
- electrolyte beverage
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Vasomotor Symptoms
Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women
The purpose of the study is to evaluate the efficacy and safety of Desvenlafaxine Succinate (DVS) Sustained Release (SR), in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) in menopausal women.
- Trial name
- NCT00683800
- Testing
- desvenlafaxine succinate (DVS) SR
- Where
- 121 sites in United States, Canada
- Volunteers
- 2,186 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vasomotor Symptoms, Menopausal Symptoms
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)
This is a two-part study designed to evaluate the effect of Estetrol (E4) 15 or 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) (Efficacy Study Part) and the safety of E4 20 mg (Endometrial and General…
- Trial name
- NCT04209543
- Testing
- Estetrol, Progesterone
- Where
- 224 sites in United States, Argentina and 12 more
- Volunteers
- 1,570 people, healthy volunteers welcome
- Sponsor
- Estetra
Healthy
A Randomized, Double Blind, Placebo Controlled, Clinical Study to Examine the Benefits of an Oral Product in Panelists With Menopausal Symptoms Including Vasomotor Symptoms (VMS).
Randomized, Double-Blind, Placebo-Controlled, Single-Center Clinical Study with a Run-in Baseline, Daily Diary Log, and Validated Questionnaires (Greene GCS) with Oral Dietary Supplement
- Trial name
- NCT07033013
- Testing
- Dietary Supplement with actives
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Olly, PBC
Hot Flashes
Clinical Trial Assessing Toxicity and Efficacy of MF101 for Hot Flashes
The researchers propose a Phase II randomized, double-blind, placebo-controlled trial of 180 healthy postmenopausal women experiencing at least 5 hot flashes per day or 35 hot flashes per week.
- Trial name
- NCT00119665
- Testing
- MF101
- Where
- 4 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Bionovo
Mild Gastrointestinal Symptoms in Healthy Adults, Low-grade Chronic Inflammation
Fungal Fiber for Gut Health
This study compares effects of plant based fiber vs fungi based fiber on clinical outcomes related to gut function (immunity, emotions, stress) and explores the role of gut microbiome structure and function on individual…
- Conditions
- Mild Gastrointestinal Symptoms in Healthy Adults, Low-grade Chronic Inflammation, Stress, Gut Health
- Trial name
- FUN4GUT (NCT06404749)
- Testing
- fungal fiber, inulin
- Where
- Argentina
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Future Biome SA
Joint Discomfort, Joint Pain, Stiffness, Function
JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women
The goal of this interventional study is to evaluate whether the study product can help improve quality of life and reduce common menopause symptoms-such as joint discomfort, hot flashes and night sweats-in women aged 50-70.
- Conditions
- Joint Discomfort, Joint Pain, Stiffness, Function, Joint Pain, Hot Flashes
- Trial name
- NCT07238478
- Testing
- JDS-HF3.0
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Bonafide Health
Glycemic Response, Menopause Symptoms
Impact of Reducose® on Glycemic Response and Menopausal Symptoms in Perimenopausal Women (CALM-R)
The purpose of this double-blind, randomized, placebo-controlled trial is to. evaluate daily Reducose® (mulberry leaf extract) supplementation taken with the two largest meals for 12 weeks on improving glycemic response and…
- Trial name
- CALM-R (NCT07333885)
- Testing
- Reducose® (Mulberry leaf extract)
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Phynova Group Ltd
Menopause
Open-labelled Study to Evaluate the Effect of SE5-OH Tablets on Healthy Women With Menopausal Symptoms
Multicentre, exploratory, prospective, open-labelled study to evaluate the efficacy of SE5-OH tablets on menopausal symptoms in healthy women experiencing menopausal symptoms after 12 weeks of administration.
- Trial name
- NCT06398236
- Testing
- SE5-OH tablets
- Where
- Spain
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Nutrition & Sante Iberia
Vulvar and Vaginal Atrophy
To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women.
This is a Randomized, Parallel-Group, Placebo- Controlled, Multicenter Study to Evaluate the Therapeutic Equivalence and Safety of Estradiol Vaginal Tablets 10 mcg and Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk…
- Trial name
- NCT02668796
- Testing
- Estradiol Vaginal Tablets 10 mcg (Glenmark), Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)
- Where
- United States
- Volunteers
- 522 people, healthy volunteers welcome
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Postmenopausal Symptoms
Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women
The purpose of this study is to assess the pharmacokinetics (absorption, breakdown and elimination from the body), safety and tolerability of Brisdelle (paroxetine mesylate) Capsules 7.5 mg when given as a single dose and…
- Trial name
- N30-005 (NCT01829919)
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Noven Therapeutics
Menopause, Vasomotor System
Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women
The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo for the treatment of Vasomotor Symptoms (VMS)…
- Trial name
- NCT00369434
- Testing
- Desvenlafaxine succinate sustained-release (DVS SR)
- Where
- 34 sites in United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Vasomotor Symptoms
Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause
The purpose of this study is to assess the efficacy and safety of 4 doses of desvenlafaxine-233 sustained release (DVS-233 SR) as compared to placebo for the treatment of moderate to severe vasomotor symptoms associated with…
- Trial name
- NCT00421031
- Testing
- DVS-233 SR
- Where
- 41 sites in United States
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Menopausal Symptoms
Efficacy of CL22205 on Bone Mineral Density and Menopausal Symptoms
The purpose of this study is to evaluate the effect of CL22205 on bone mineral density and menopausal symptoms in women.
- Trial name
- NCT06899243
- Testing
- CL22205
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eetho Brands, Inc
Primary Ovarian Insufficiency, Vaginitis
A Study To Compare The Amount Of Premarin Components That Is Absorbed Into The Blood Of Japanese Healthy Postmenopausal Women Following Oral Administration Of Two Different Tablets Of Premarin Under Fast and Fed Conditions.
The purpose of this study is to assess the bioequivalence and food effect for a new Premarin formulation compared with a Premarin reference tablet in Japanese healthy postmenopausal women.
- Conditions
- Primary Ovarian Insufficiency, Vaginitis, Metrorrhagia, Menopause
- Trial name
- NCT01436513
- Testing
- Premarin reference tablet (fasted), Premarin new tablet (fasted), Premarin reference tablet (fed)
- Where
- Japan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hot Flashes
A Clinical Trial Assessing Safety of MF101 for Hot Flushes
This Phase 1, open label, randomized clinical trial will enroll 40 generally healthy, postmenopausal women aged 40-65 years old. Women will be randomized to one of two oral doses of MF101 for 4 weeks.
- Trial name
- NCT01300078
- Testing
- MF101
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bionovo
Fatigue
Radicle Women's HealthTM: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes Among Women Experiencing Menopausal Symptoms
Radicle Women's HealthTM: A randomized, double-blind, placebo- controlled direct-to-consumer study assessing the impact of health and wellness products on fatigue and related health outcomes among women experiencing menopausal…
- Trial name
- NCT07572578
- Testing
- Fatigue Active Product 1
- Where
- United States
- Volunteers
- 502 people, healthy volunteers welcome
- Sponsor
- Radicle Science
Menopause, Postmenopausal Vaginal Atrophy
Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis
This trial is conducted in Europe. The purpose of this study is to evaluate endometrial safety of intravaginal estradiol (Vagifem®) in healthy postmenopausal women having atropic vaginitis.
- Trial name
- NCT00431132
- Testing
- estradiol, 10 mcg
- Where
- 42 sites in Czechia, Denmark and 5 more
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Hot Flushes, Vasomotor Symptoms
A Study of MF101 in Postmenopausal Women
This phase 3a study is designed to assess the safety and efficacy of MF101 on the frequency of moderate to severe hot flushes in postmenopausal women.
- Trial name
- HERBA (NCT00906308)
- Testing
- MF101 5 g/day, MF101 10 g/day
- Where
- 50 sites in United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Bionovo
Hot Flashes
Safety and Efficacy of Dr. Tagliaferri's Menopause Formula
The primary goal of this study is to evaluate the safety and efficacy of 12 weeks of treatment of 4 grams/day of Dr. Tagliaferri's Menopause Formula (administered as 2 grams PO BID) in reducing the frequency of menopausal…
- Trial name
- NCT01957306
- Testing
- Dr. Tagliaferri's Menopause Formula
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Herba Buena, Inc